在胃癌中,PI3表达预测了用破坏DNA的药物进行化疗后的复发
Kenji Harada1,2, Naoya Sakamoto1,2,3, Takumi Kitaoka3,4
1Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
The Journal of pathology
|February 21, 2025
概括
胃癌有机体显示酶抑制剂3 (PI3) 作为预测化疗耐药性的生物标志物. 过度表达PI3与较差的结局和复发风险相关,这表明它可以用于选择非DNA损伤剂.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 化疗耐药性和选择最佳治疗方案是胃癌治疗中的重大挑战.
- 胃癌有机体 (GCOs) 为研究瘤生物学和药物敏感性提供了一个比细胞系更准确的模型.
- 确定可靠的生物标志物对于预测治疗反应和患者预后至关重要.
研究的目的:
- 用GCOs识别新的生物标志物来预测胃癌中的多药性耐药性.
- 研究已识别的生物标志物在耐药性机制中的作用及其与患者结果的关联.
主要方法:
- 建立和药物敏感性测试的5-甲和氧化耐药的GCOs.
- RNA测序分析以确定差异表达的基因.
- 在原始和公共队列中验证生物标志物与患者预后和化疗疗效能的关联,包括单细胞RNA测序数据.
主要成果:
- 酶抑制剂3 (PI3) 的表达增加在耐药的GCO中一直被观察到.
- 过度表达PI3与核糖体生物合成和RNA代谢有关.
- PI3促进了对5-甲,甲和甲的耐药性,但不是对帕克利塔塞尔的耐药性.
- 患者的PI3阳性与预后较差,复发风险增加和DNA破坏性化疗后预测的复发相关.
结论:
- 酶抑制剂3 (PI3) 是预测胃癌多药性耐药性的潜在生物标志物.
- PI3表达通过RNA和核糖体代谢途径影响耐药性.
- 对于胃癌患者来说,PI3可能会指导选择非破坏DNA的治疗剂.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...